Document is current
Any future updates will be listed below
-
Authors
Palacios, Florencia
Yan, Xiao-Jie https://orcid.org/0000-0002-3717-5803
Ferrer, Gerardo https://orcid.org/0000-0002-4084-6815
Chen, Shih-Shih
Vergani, Stefano
Yang, Xuejing
Gardner, Jeffrey
Barrientos, Jaqueline C.
Rock, Philip
Burack, Richard https://orcid.org/0000-0002-5584-584X
Kolitz, Jonathan E.
Allen, Steven L. https://orcid.org/0000-0002-3482-3182
Kharas, Michael G. https://orcid.org/0000-0002-1165-6991
Abdel-Wahab, Omar
Rai, Kanti R.
Chiorazzi, Nicholas https://orcid.org/0000-0003-1023-6650
- License Information
-
More Information
Article History
Received: 13 June 2020
Revised: 4 November 2020
Accepted: 14 December 2020
First Online: 27 January 2021
Compliance with ethical standards
:
: The authors declare no direct competing financial interests. NC and S-SC have received research support for studies independent of those reported here from Pharmacyclics, Inc., argenx, and Verastem Oncology. OA-W has served as a consultant for H3 Biomedicine, Foundation Medicine Inc., Merck, and Janssen, and serves on the Scientific Advisory Board of Envisagenics, Inc., and has received research funding from H3 Biomedicine unrelated to the current manuscript. JCB has received honoraria for consulting for Gilead, AstraZeneca, Janssen, Sandoz, Genentech, Bayer, and Celgene.
